PATENT--FEE

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

Applicant:

ALAIN CLAUDE-MARIE DAUGAN

Continuation of Serial No.
09/633,431 filed August 7, 2000

Filed: Herewith

For: **TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE**

Group Art Unit: 1624

Examiner: T. Truong

Attorney Docket No. 29342/38166

"EXPRESS MAIL" mailing label No. **EK657815914US**

Date of Deposit:
February 5, 2002

I hereby certify that this paper (or fee) is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR §1.10 on the date indicated above and is addressed to:
Commissioner of Patents,
Washington, D.C. 20231.

Richard Zimmermann

PRELIMINARY AMENDMENT ACCOMPANYING NEW APPLICATION TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above-identified application filed under 37 C.F.R. 1.53(b), as follows:

IN THE SPECIFICATION:

Page 1, after the title, please insert:

--CROSS-REFERENCE TO RELATED APPLICATIONS


This application is a continuation of copending application Serial No. 09/633,431, filed on August 7, 2000, now U.S. Patent No. _____, which is a continuation of copending application Serial No. 09/399,667, filed on September 21, 1999, now U.S. Patent No. 6,127,542, which is a continuation of application Serial No. 09/133,078, filed on August 12, 1998, now U.S. Patent No. 6,025,494, which is a divisional of application Serial No. 08/669,389, filed on July 16, 1996, now U.S. Patent No. 5,859,006.--

IN THE CLAIMS:

Cancel claims 1-17, inclusive, without prejudice.

Add new claims 18-20 as follows:

--18. A method of elevating cGMP levels in a human or nonhuman animal body, which comprises administering to said body a therapeutically effective amount of a compound having a formula




or salts or solvates thereof, in which:

R^0 represents hydrogen, halogen, or C_{1-6}alkyl;

R^1 represents hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, haloC_{1-6}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkylC_{1-3}-alkyl, arylC_{1-3}alkyl, wherein aryl is phenyl or phenyl substituted with one to three substituents selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-4}alkoxy, methylenedioxy, and mixtures thereof, or heteroarylC_{1-3}-alkyl, wherein heteroaryl is thienyl, furyl or pyridyl, each optionally substituted with one to three substituents selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkoxy, and mixtures thereof;

R^2 represents an optionally substituted monocyclic aromatic ring, selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring;




attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; and

R^3 represents hydrogen or C_{1-6}alkyl, or R^1 or R^3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring.

19. A method of potentiating an effect of endothelium-derived relaxing factor, a nitrovasodilator, atrial natriuretic factor, brain natriuretic peptide, a

C-type natriuretic peptide, or an endothelium-dependent relaxing agent in a human or nonhuman animal body, which comprises administering to said body a therapeutically effective amount of a compound having a formula




or salts or solvates thereof, in which:

R^0 represents hydrogen, halogen, or C_{1-6}alkyl;

R^1 represents hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, haloC_{1-6}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkylC_{1-3}-alkyl, arylC_{1-3}alkyl, wherein aryl is phenyl or phenyl substituted with one to three substituents selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-4}alkoxy, methylenedioxy, and mixtures thereof, or heteroarylC_{1-3}-alkyl, wherein heteroaryl is thienyl, furyl or pyridyl, each optionally substituted with one to three substituents selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkoxy, and mixtures thereof;

R^2 represents an optionally substituted monocyclic aromatic ring, selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring;



attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; and

R^3 represents hydrogen or C_{1-6}alkyl, or R^1 or R^3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring.

20. The method of claim 19 wherein the endothelium-dependent relaxing agent is bradykinin, acetylcholine, or 5-HT.--

SUBSTITUTE SHEET (RULE 26)

REMARKS

Claims 1-17 are pending in the application. Claims 1-17, previously prosecuted in prior applications, have been cancelled without prejudice. Therefore, claims 18-20 are at issue in this continuation application.

This preliminary amendment adds no new matter. The specification has been amended to insert a cross-reference to a related application. New claims 18-20 are supported in the specification at page 6, lines 19-30, and page 7, lines 33-35, for example.

The amendments are described in more detail below. Pursuant to 37 C.F.R. §1.121, a marked-up version of the changes made to the specification and claims by the present amendment is attached hereto following the signature page of this amendment. The first page of the marked-up version of the changes is captioned "Version With Markings to show Changes Made."

It is submitted that new claims 18-20 should be entered, and that claims 18-20 are of proper form and scope for allowance. Early and favorable action on the merits is respectfully requested.

Express Mail Label No. EV325917495US

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By 

James J. Napoli
(Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois
February 5, 2002

Express Mail Label No. EL 955 914 925 US

VERSION WITH MARKINGS TO SHOW CHANGES MADE
(29342/38166, filed February 5, 2002)

IN THE SPECIFICATION:

A cross reference to related applications has been added to page 1, after the title, as follows:

CROSS-REFERENCE TO RELATED APPLICATIONS


This application is a continuation of co-pending application Serial No. 09/633,431, filed on August 7, 2000, now U.S. Patent No. _____, which is a continuation of copending application Serial No. 09/399,667, filed on September 21, 1999, now U.S. Patent No. 6,127,542, which is a continuation of application Serial No. 09/133,078, filed on August 12, 1998, now U.S. Patent No. 6,025,494, which is a divisional of application Serial No. 08/669,389, filed on July 16, 1996, now U.S. Patent No. 5,859,006.

IN THE CLAIMS:

Claims 1-17, inclusive, have been cancelled without prejudice.

New claims 18-20 have been added as follows:

18. A method of elevating cGMP levels in a human or nonhuman animal body, which comprises administering to said body a therapeutically effective amount of a compound having a formula




or salts or solvates thereof, in which:

R^0 represents hydrogen, halogen, or C_{1-6}alkyl;

R^1 represents hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, haloC_{1-6}alkyl, C_{3-8}cycloalkyl, C_{3-8}cycloalkylC_{1-3}alkyl, arylC_{1-3}alkyl, wherein aryl is phenyl or phenyl substituted with one to three substituents selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-4}alkoxy, methylenedioxy, and mixtures thereof, or heteroarylC_{1-3}alkyl, wherein heteroaryl is thienyl, furyl or pyridyl, each optionally substituted with one to three substituents selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkoxy, and mixtures thereof;


R^2 represents an optionally substituted monocyclic aromatic ring, selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring;



attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; and

R^3 represents hydrogen or C_{1-6}alkyl, or R^1 or R^3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring.

19. A method of potentiating an effect of endothelium-derived relaxing factor, a nitrovasodilator, atrial natriuretic factor, brain natriuretic peptide, a C-type natriuretic peptide, or an endothelium-dependent relaxing agent in a human or nonhuman animal body, which comprises administering to said body a therapeutically effective amount of a compound having a formula




or salts or solvates thereof, in which:

R^0 represents hydrogen, halogen, or C_{1-6}-alkyl;

R^1 represents hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, haloC_{1-6}alkyl, C_{3-8}cycloalkyl, C_{3-8}-cycloalkylC_{1-3}alkyl, arylC_{1-3}alkyl, wherein aryl is phenyl or phenyl substituted with one to three substituents selected from the group consisting of

halogen, C_{1-6}alkyl, C_{1-4}alkoxy, methylenedioxy, and mixtures thereof, or heteroarylC_{1-3}alkyl, wherein heteroaryl is thienyl, furyl or pyridyl, each optionally substituted with one to three substituents selected from the group consisting of halogen, C_{1-6}alkyl, C_{1-6}alkoxy, and mixtures thereof;

R^2 represents an optionally substituted monocyclic aromatic ring, selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring;



attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen; and

R^3 represents hydrogen or C_{1-6}alkyl, or R^1 or R^3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring.

20. The method of claim 19 wherein the endothelium-dependent relaxing agent is bradykinin, acetylcholine, or 5-HT.